Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Comment by BioTeckon May 12, 2022 6:24pm
191 Views
Post# 34679718

RE:RE:RE:Markets

RE:RE:RE:MarketsMoney, you are assuming they will have the listing completed before any deal. Look at the state of the TSX and Venture exchanges. The crash is only starting so I think that short of a deal with some MAJOR pharma, the outlook is grim. Then again, you never really know what will happen but my bet is it will be lacklustre. The timing is awful and would have been much better when the market was in euphoria. This is also assuming that they will even get any deal done in the near future. 


I'm still convinced by the trading and tight range that the price is being kept at 1.40 for some kind of $ transaction. The only thing that makes sense to me is the pharma will give SVA money in exchange for shares on top of whatever the deal will entail. At which price, I have no idea but I'm feeling very certain that there will be dilution. 


The second problem is there are a lot of investors who are tired of holding and have made 10x and ready to get out of their large positions to sit on cash until the market begins to show some signs of recovery. Unless there is new demand, it will put a lot of downward pressure on the price should they not like the deal and want to stay vested. Keep in mind there are millions of warrants that will be in the money at 1.70. I could even expect those folks to short the stock on any price increase above 2.00.


My guess is we don't see anything sustainable North of $2.00 in the best case scenario. Could be wrong (hopefully I am) but that is my analysis of the current situation. 









MoneyMouth wrote: Do you think an uplisting to the TSX could create enough buying pressure combat the selling pressure on news?


<< Previous
Bullboard Posts
Next >>